A Multicenter Study of Secukinumab, With a Randomized Double-blind, Placebo-controlled Withdrawal-retreatment Period, to Evaluate Maintenance of Response in Participants With Non-radiographic Axial Spondyloarthritis Who Achieved Remission

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 08 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Secukinumab (Primary)
Indications Non-radiographic axial spondyloarthritis
Focus Therapeutic Use
Sponsors Novartis; Novartis Pharma A.G.

Most Recent Events

24 Dec 2024 Planned End Date changed from 19 Jun 2030 to 21 Jun 2030.
24 Dec 2024 Planned primary completion date changed from 24 Apr 2030 to 26 Apr 2030.
28 May 2024 As per Eudra the status of the trial is "trial now transitioned" in France. Hence, retained the status of the trial as per the other source.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight